Ratios Glaxo Smith Kline
-
Upload
naveed-arain -
Category
Documents
-
view
240 -
download
1
Transcript of Ratios Glaxo Smith Kline
Description Dec 31, 2010
Net sales 18,916,191
Cost of sales -14,063,242
Gross profit 4,852,949
Selling, marketing and distribution expenses -2,301,516
Administrative expenses -826,236
Other operating expenses -171,143
Other operating income 397,696
Operating Profit 1,951,750
Financial charges -20,026
Profit before taxation 1,931,724
Taxation -874,341
Profit after taxation for the year 1,057,383
Other comprehensive income
Fair value gain on available-for-sale investments 3,544
Reversal of deficit on revaluation of available-for-sale investments 0
Deferred tax thereon -1,240
2,304Total comprehensive income 1,059,687
Earnings per share 4.42
Stock Price Per Share 88.4
Total outstanding shares 31,771,778
Net Sales Per Share 0.60
Income Statement
Glaxo Smith Kline (GSK)
As of 31st December 2010, 2011, 2012
Rs in (000)
Dec 31, 2011 Dec 31, 2012
21,750,147 23,149,964
-15,931,728 -17,068,949
5,818,419 6,081,015
-2,790,373 -3,046,675
-1,022,493 -771,322
-194,066 -192,617
461,927 289,207
2,273,414 2,359,608
-36,526 -47,512
2,236,888 2,312,096
-1,095,972 -992,000
1,140,916 1,320,096
0 0
128 0
-45 0
83 0
1,140,999 1,320,096
4.77 5.02
73.93 73.31
239,269,179 263,196,097
0.09 0.09
Income Statement
Glaxo Smith Kline (GSK)
As of 31st December 2010, 2011, 2012
Rs in (000)
Description Dec 31, 2010
EQUITY AND LIABILITIES
CURRENT LIABILITIES
Trade and other payables 3,429,292
Provisions 131,001
TOTAL CURRENT LIABILITIES 3,560,293
NON-CURRENT LIABILITIES
Staff retirement benefits 115,240
Deferred taxation 416,452
TOTAL NON-CURRENT LIABILITIES 531,692
TOTAL LIABILITIES 4,091,985
SHARE CAPITAL AND RESERVES
Share capital 1,964,118
Reserves 8,835,696
Shareholder's Equity 10,799,814
TOTAL EQUITY AND LIABILITIES 14,891,799
ASSETS
NON-CURRENT ASSETS
Fixed assets
Property, plant and equipment 4,189,996
Intangible - Goodwill 955,742
Long-term loans to employees 73,590
Long-term deposits 11,871
Total Non-current Assets 5,231,199
CURRENT ASSETS
Stores and spares 150,632
Stock-in-trade 4,312,535
Trade debts 295,762
Loans and advances 144,267
Trade deposits and prepayments 96,234
Interest accrued 19,443
Refunds due from government 17,534
Other receivables 290,056
Taxation - payments less provision 623,410
Balance Sheet
Glaxo Smith Kline (GSK)
As of 31st December 2010, 2011, 2012
Rs. in (000)
Investments 901,955
Cash and bank balances 2,808,772
Total Current Assets 9,660,600
TOTAL ASSETS 14,891,799
Dec 31, 2011 Dec 31, 2012
3,663,772 3,950,339
217,239 200,716
3,881,011 4,151,055
19,706 50,381
428,296 570,298
448,002 620,679
4,329,013 4,771,734
2,392,691 2,631,960
8,715,881 8,839,631
11,108,572 11,471,591
15,437,585 16,243,325
4,771,175 5,784,694
955,742 955,742
82,005 81,959
11,780 16,761
5,820,702 6,839,156
159,268 170,501
5,602,526 5,080,220
343,404 350,362
163,378 243,070
54,657 92,542
30,372 12,205
17,104 40,759
319,800 438,674
600,742 660,092
Balance Sheet
Glaxo Smith Kline (GSK)
As of 31st December 2010, 2011, 2012
Rs. in (000)
196,706 198,118
2,128,926 2,117,626
9,616,883 9,404,169
15,437,585 16,243,325
Description Dec 31, 2010
Net sales 100.00%
Cost of sales -74.34%
Gross profit 25.66%
Selling, marketing and distribution expenses -12.17%
Administrative expenses -4.37%
Other operating expenses -0.90%
Other operating income 2.10%
Operating Profit 10.32%
Financial charges -0.11%
Profit before taxation 10.21%
Taxation -4.62%
Profit after taxation for the year 5.59%
Other comprehensive income
Fair value gain on available-for-sale investments 0.02%
Reversal of deficit on revaluation of available-for-sale investments 0%
Deferred tax thereon -0.01%
Total comprehensive income 5.60%
Earnings per share 0.00%
Vertical Analysis Of Income Statement
Glaxo Smith Kline (GSK)
As of 31st December 2010, 2011, 2012
Rs. in (000)
Dec 31, 2011 Dec 31, 2012
100.00% 100.00%
-73.25% -73.73%
26.75% 26.27%
-12.83% -13.16%
-4.70% -3.33%
-0.89% -0.83%
2.12% 1.25%
10.45% 10.19%
-0.17% -0.21%
10.28% 9.99%
-5.04% -4.29%
5.25% 5.70%
0.00% 0.00%
0.00% 0.00%
0.00% 0.00%
5.25% 5.70%
0.00% 0.00%
Vertical Analysis Of Income Statement
Glaxo Smith Kline (GSK)
As of 31st December 2010, 2011, 2012
Rs. in (000)
Description Dec 31, 2010
EQUITY AND LIABILITIES
CURRENT LIABILITIES
Trade and other payables 23.03%
Provisions 0.88%
TOTAL CURRENT LIABILITIES 23.91%
NON-CURRENT LIABILITIES
Staff retirement benefits 0.77%
Deferred taxation 2.80%
TOTAL NON-CURRENT LIABILITIES 3.57%
TOTAL LIABILITIES 27.48%
SHARE CAPITAL AND RESERVES
Share capital 13.19%
Reserves 59.33%
Shareholder's Equity 72.52%
TOTAL EQUITY AND LIABILITIES 100.00%
ASSETS
NON-CURRENT ASSETS
Fixed assets
Property, plant and equipment 28.14%
Intangible - Goodwill 6.42%
Long-term loans to employees 0.49%
Long-term deposits 0.08%
Total Non-current Assets 35.13%
CURRENT ASSETS
Stores and spares 1.01%
Stock-in-trade 28.96%
Trade debts 1.99%
Loans and advances 0.97%
Trade deposits and prepayments 0.65%
Interest accrued 0.13%
Refunds due from government 0.12%
Other receivables 1.95%
Taxation - payments less provision 4.19%
Vertical Analysis of Balance Sheet
Glaxo Smith Kline (GSK)
As of 31st December 2010, 2011, 2012
Rs. in Rupees
Investments 6.06%
Cash and bank balances 18.86%
Total Current Assets 64.87%
TOTAL ASSETS 100.00%
Dec 31, 2011 Dec 31, 2012
23.73% 24.32%
1.41% 1.24%
25.14% 25.56%
0.13% 0.31%
2.77% 3.51%
2.90% 3.82%
28.04% 29.38%
15.50% 16.20%
56.46% 54.42%
71.96% 70.62%
100.00% 100.00%
30.91% 35.61%
6.19% 5.88%
0.53% 0.50%
0.08% 0.10%
37.70% 42.10%
1.03% 1.05%
36.29% 31.28%
2.22% 2.16%
1.06% 1.50%
0.35% 0.57%
0.20% 0.08%
0.11% 0.25%
2.07% 2.70%
3.89% 4.06%
Vertical Analysis of Balance Sheet
Glaxo Smith Kline (GSK)
As of 31st December 2010, 2011, 2012
Rs. in Rupees
1.27% 1.22%
13.79% 13.04%
62.30% 57.90%
100.00% 100.00%
Description Dec 31, 2010 Dec 31, 2011
Net sales 100.0% 114.98%
Cost of sales 100.0% 113.29%
Gross profit 100.0% 119.89%
Selling, marketing and distribution expenses 100.0% 121.24%
Administrative expenses 100.0% 123.75%
Other operating expenses 100.0% 113.39%
Other operating income 100.0% 116.15%
Operating Profit 100.0% 116.48%
Financial charges 100.0% 182.39%
Profit before taxation 100.0% 115.80%
Taxation 100.0% 125.35%
Profit after taxation for the year 100.0% 107.90%
Other comprehensive income
Fair value gain on available-for-sale investments 100.0% 0.00%Reversal of deficit on revaluation of available-for-
sale investments 0.0% 0.00%
Deferred tax thereon 100.0% 3.63%
100.0% 3.60%Total comprehensive income 100.0% 107.67%
Earnings per share 100% 107.92%
Horizontal Analysis Of Income Statement
Glaxo Smith Kline (GSK)
As of 31st December 2010, 2011, 2012
Rs. in (000)
Dec 31, 2012
122.38%
121.37%
125.31%
132.38%
93.35%
112.55%
72.72%
120.90%
237.25%
358.15%
119.69%
124.85%
0.00%
0.00%
0.00%
0.00%
124.57%
113.57%
Horizontal Analysis Of Income Statement
Glaxo Smith Kline (GSK)
As of 31st December 2010, 2011, 2012
Rs. in (000)
Description Dec 31, 2010
EQUITY AND LIABILITIES
CURRENT LIABILITIES
Trade and other payables 100.00%
Provisions 100.00%
TOTAL CURRENT LIABILITIES 100.00%
NON-CURRENT LIABILITIES
Staff retirement benefits 100.00%
Deferred taxation 100.00%
TOTAL NON-CURRENT LIABILITIES 100.00%
TOTAL LIABILITIES 100.00%
SHARE CAPITAL AND RESERVES
Share capital 100.00%
Reserves 100.00%
Shareholder's Equity 100.00%
TOTAL EQUITY AND LIABILITIES 100.00%
ASSETS
NON-CURRENT ASSETS
Fixed assets
Property, plant and equipment 100.00%
Intangible - Goodwill 100.00%
Long-term loans to employees 100.00%
Long-term deposits 100.00%
Total Non-current Assets 100.00%
CURRENT ASSETS
Stores and spares 100.00%
Stock-in-trade 100.00%
Trade debts 100.00%
Loans and advances 100.00%
Trade deposits and prepayments 100.00%
Interest accrued 100.00%
Refunds due from government 100.00%
Other receivables 100.00%
Taxation - payments less provision 100.00%
Horizontal Analysis Balance Sheet
Glaxo Smith Kline (GSK)
As of 31st December 2010, 2011, 2012
Rs. in Rupees
Investments 100.00%
Cash and bank balances 100.00%
Total Current Assets 100.00%
TOTAL ASSETS 100.00%
Dec 31, 2011 Dec 31, 2012
106.84% 115.19%
165.83% 153.22%
109.01% 116.59%
17.10% 43.72%
102.84% 136.94%
84.26% 116.74%
105.79% 116.61%
121.82% 134.00%
98.64% 100.04%
102.86% 106.22%
103.67% 109.08%
113.87% 138.06%
100.00% 100.00%
111.43% 111.37%
99.23% 141.19%
111.27% 130.74%
105.73% 113.19%
129.91% 117.80%
116.11% 118.46%
113.25% 168.49%
56.80% 96.16%
156.21% 62.77%
97.55% 232.46%
110.25% 151.24%
110.25% 105.88%
Horizontal Analysis Balance Sheet
Glaxo Smith Kline (GSK)
As of 31st December 2010, 2011, 2012
Rs. in Rupees
21.81% 21.97%
75.80% 75.39%
99.55% 97.35%
103.67% 109.08%
2010
Definition:
Current Assets 2.71 =
Current Liabilities
Total quick assets 1.50 =
Current Liabilities
Current Liabilities 0.83 =
Inventory
Total cash assets 0.79 =
Current Liabilities
365 Days 115.84 =
Inventory Turnover Ratio
365 Days 5.60 =
Recivable Turnover Ratio
365 Days 5.71 =
Payable Turnover Raito
115.73
Liquidity Measurement Ratios
Glaxo Smith Kline (GSK)
For
2010, 2011, 2012
1 Current Ratio =
2 Quick Ratio =
3Current Liabilities to
Inventory Ratio=
4 Cash Ratio =
5Average Inventory
Processing Period (AIPP)=
6Average Recivable
Collection Period (ARCP)=
AIPP + ARCP - APPP
7Averagepayable Payment
Period (APPP)=
8 Cash Conversion Cycle =
2.71
2.48
3.00
2.48
1.50
1.03
0.83
0.69 0.79
0.55
0.00
0.50
1.00
1.50
2.00
2.50
2010 2011
115.84 113.58
5.60 5.37 5.71 5.76
115.73 113.18
0.00
20.00
40.00
60.00
80.00
100.00
120.00
140.00
2010 2011
2011 2012
9,660,600.00 2.48 = 9,616,883.00 2.27 = 9,404,169.00
3,560,293.00 3,881,011.00 4,151,055.00
5,348,065.00 1.03 = 4,014,357.00 1.04 = 4,323,949.00
3,560,293.00 3,881,011.00 4,151,055.00
3,560,293.00 0.69 = 3,881,011.00 0.82 = 4,151,055.00
4,312,535.00 5,602,526.00 5,080,220.00
2,808,772.00 0.55 = 2,128,926.00 0.51 = 2,117,626.00
3,560,293.00 3,881,011.00 4,151,055.00
365 113.58 = 365 114.22 = 3653.15 3.21 3.20
365 5.37 = 365 6.92 = 365
65.22 68.01 52.77
365 5.76 = 365 5.52 = 365
63.95747594 63.33690638 66.07441446
Days 113.18 Days 115.61 Days
Liquidity Measurement Ratios
Glaxo Smith Kline (GSK)
For
2010, 2011, 2012
Current Ratio
2.27
1.04
0.82
0.51
2012
Current Ratio
Quick Ratio
Current Liabilities toInventory Ratio
Cash Ratio
114.22
6.92 5.52
115.61
2012
Average Inventory Processing Period (AIPP)
Average Recivable Collection Period (ARCP)
Averagepayable Payment Period (APPP)
Cash Conversion Cycle
2010
Net Income 7.10% =
Total Assets
Net Income 9.79% =
Owners' Equity
Gross Profit 25.66% =
Net Sales
Operating Profit 10.32% =
Net Sales
Net Income 5.59% =
Net Sales
Earnings Before Interest and Taxes 13.11% =
Total Assets
Profitability Indicator Ratios
Glaxo Smith Kline (GSK)
As of 31st December 2010, 2011, 2012
Rs. in Rupees
Definition:
1Return on Assets Ratio =
2Return on Equity Ratio =
3=
6=
Gross Profit Margin
Ratio
Operating Profit Margin
Ratio
Net Profit Margin Ratio
Basic Earnings Power
Ratio
4=
5=
25.66% 26.75%
20.00%
25.00%
30.00%
7.10% 7.39%
9.79% 10.27% 10.32% 10.45%
5.59% 5.25%
13.11%
14.73%
0.00%
5.00%
10.00%
15.00%
2010 2011
2011 2012
1,057,383.00 7.39% = 1,140,916.00 8.13% = 1,320,096.00
14,891,799.00 15,437,585.00 16,243,325.00
1,057,383.00 10.27% = 1,140,916.00 11.51% = 1,320,096.00
10,799,814.00 11,108,572.00 11,471,591.00
4,852,949.00 26.75% = 5,818,419.00 26.27% = 6,081,015.00
18,916,191.00 21,750,147.00 23,149,964.00
1,951,750.00 10.45% = 2,273,414.00 10.19% = 2,359,608.00
18,916,191.00 21,750,147.00 23,149,964.00
1,057,383.00 5.25% = 1,140,916.00 5.70% = 1,320,096.00
18,916,191.00 21,750,147.00 23,149,964.00
1,951,750.00 14.73% = 2,273,414.00 14.53% = 2,359,608.00
14,891,799.00 15,437,585.00 16,243,325.00
Profitability Indicator Ratios
Glaxo Smith Kline (GSK)
As of 31st December 2010, 2011, 2012
Rs. in Rupees
26.27% Return on Assets Ratio
Return on Equity Ratio
Gross Profit Margin Ratio
8.13%
11.51% 10.19%
5.70%
14.73% 14.53%
2012
Gross Profit Margin Ratio
Operating Profit MarginRatio
Net Profit Margin Ratio
Basic Earnings Power Ratio
Definition:
Total Liabilities 27.48% =
Total Assets
Earnings Before Interest and Taxes 97.46% =
Interest Expense
Long-Term Debs 0.11% =
Long-Term Debs + Owners' Equity
Total Debts 0.05 =
Owners' Equity4 Debt/Equity Ratio =
3 Capitalization Ratio =
2Interest Coverage Ratio
=
Debt Ratios
ABBOT
For
2010, 2011, 2012,
1 Total Debt Ratio =
27.48% 28.04%
97.46%
62.24%
0.11% 0.11%0.05
0.00%
20.00%
40.00%
60.00%
80.00%
100.00%
120.00%
0.11% 0.11%0.00%
2010 2011
2010 2011
28.04% = 29.38% =
62.24% = 49.66% =
0.11% = 0.15% =
11,871.00 + 10,799,814.00 11,780.00 + 11,108,572.00
0.04 = 0.05 =
10,799,814.00 11,108,572.00
531,692.00 448,002.00
2,002,600.00 3,652,600.00
11,871.00 11,780.00
1,951,750.00 2,273,414.00
Debt Ratios
ABBOT
For
2010, 2011, 2012,
4,091,985.00 4,329,013.00
14,891,799.00 15,437,585.00
29.38%
49.66%
0.11% 0.15% 0.04 0.05
Total Debt Ratio
Interest CoverageRatioCapitalization Ratio
Debt/Equity Ratio
0.11% 0.15%
2011 2012
2012
16,761.00 + 11,471,591.00
11,471,591.00
620,679.00
2,359,608.00
4,751,200.00
16,761.00
Debt Ratios
ABBOT
For
2010, 2011, 2012,
4,771,734.00
16,243,325.00
Total Debt Ratio
Interest CoverageRatioCapitalization Ratio
Debt/Equity Ratio
Definition: 2010
Cost of Good Sold 3.15 =
Average Inventory
Total Sales 65.22 =
Account Recivale
Total Sales 63.96 =
Trade Debt
Total Sales 4.51 =
Property Plant and Equipment
= Total Sales 1.27 =
Total Assets
= Total Assets 1.30 =
Owners' Equity
=
4Fixed Assets Turnover
Ratio=
5
Operating Performance Ratios
Glaxo Smith Kline (GSK)
For
2010, 2011, 2012
1 Inventory Turnover Ratio =
2Recivables Turnover
Ratio=
Total Assets Ratio
6 Asset to Equity Ratio
3 Debtors Turnover Ratio
3.15 3.21
65.22 68.01
63.96 63.34
4.51 4.56 1.27 1.41 1.30 1.43
10.00
20.00
30.00
40.00
50.00
60.00
70.00
80.00
3.15 3.21 4.51 4.56 1.27 1.41 1.30 1.43
0.00
10.00
2010 2011
2011 2012
14,063,242.00 3.21 = 15,931,728.00 3.20 = 17,068,949.00
4,463,167.00 4,957,530.50 5,341,373.00
18,916,191.00 68.01 = 21,750,147.00 52.77 = 23,149,964.00
290,056.00 319,800.00 438,674.00
18,916,191.00 63.34 = 21,750,147.00 66.07 = 23,149,964.00
295,762.00 343,404.00 350,362.00
$18,916,191 4.56 = $21,750,147 4.00 = $23,149,964
$4,189,996 $4,771,175 $5,784,694
18,916,191.00 1.41 = 21,750,147.00 1.43 = 23,149,964.00
14,891,799.00 15,437,585.00 16,243,325.00
14,063,242.00 1.43 = 15,931,728.00 1.49 = 17,068,949.00
10,799,814.00 11,108,572.00 11,471,591.00
Operating Performance Ratios
Glaxo Smith Kline (GSK)
For
2010, 2011, 2012
3.20
52.77
66.07
4.00 1.43 1.43 1.49
Inventory Turnover Ratio
Recivables Turnover Ratio
Debtors Turnover Ratio
Fixed Assets Turnover Ratio
Total Assets Ratio
Asset to Equity Ratio
3.20 4.00 1.43 1.43 1.49
2012
Profitability Ratios 2010
Definition:
Stock Price Per Share 148.51 =
Net Sales per Share
Annual Dividend per Share 0.05 =
Stock Price per Share
Stock Price Per Share 0.00 =
Total Assets-Intangible Assets-Liabilities
Stock Price per Share 20.00 =
Earnings per Share
Investment Valuation Ratios
Glaxo Smith Kline (GSK)
For
2010, 2011, 2012, 2013
1 Price/Sales Ratio =
2 Dividend Yield =
3 Price/Book Value Ratio =
4 Price/Earnings Ratio =
2.287752675 2.696322657 2.287752675
0.025156007 0.071223931 0.074257733
7.315589354 9.20242915
39.75193628
14.04022471
0
5
10
15
20
25
30
35
40
45
0.025156007 0.071223931 0.0742577330
2010 2011
2011 2012
$88.42 813.29 = $73.93 833.47 = $73.31
$0.60 $0.09 $0.09
$4.00 0.05 = $4.00 0.05 = $4.00
$88.42 $73.93 $73.31
$88.42 0.00 = $73.93 0.00 = $73.31
9,844,072 10,152,830 10,515,849
$88.42 15.50 = $73.93 14.60 = $73.31
$4.42 $4.77 $5.02
Investment Valuation Ratios
Glaxo Smith Kline (GSK)
For
2010, 2011, 2012, 2013
2.287752675 2.696322657
0.074257733 0.078499682
7.315589354 9.20242915
13.46661096 12.73890518
Price/Sales Ratio
Dividend Yield
Price/Book Value Ratio
Price/Earnings Ratio
0.074257733 0.078499682
2012 2013
S.No Ratios Name 2010 2011 2012 2013 Average
1 Current Ratios 1.72 1.45 1.25 1.08 1.38
2 Quick Ratio 1.19 1.40 0.80 0.74 1.03
3 Current Liabilities to Inventory Ratio 2.47 2.98 3.33 3.88 3.17
4 Cash Ratio 0.60 0.56 0.49 0.39 0.51
5 Average inventory processing period (AIPP) 50 56 50 50 52
6 Average receivable collection period (ARCP) 65 76 62 57 65
7 Average payables payment period (APPP) 14 26 28 33 25
8 Cash Conversion Cycle Days 101 107 84 74 91
1 Return on Assets Ratio 4.37% 11.80% 11.42% 14.11% 10%
2 Return on Equity Ratio 21.69% 50.53% 54.27% 72.19% 50%
3 Gross Profit Margin Ratio 73.26% 73.23% 70.13% 67.61% 71%
4 Operating Profit Margin Ratio 13.32% 28.51% 13.55% 27.61% 21%
5 Net Profit Margin Ratio 5.76% 19.21% 17.27% 20.51% 16%
6 Basic Earnings Power Ratio 10.49% 18.93% 18.61% 19.14% 17%
7 Earnings per Share Ratio 0.97$ 3.24$ 2.86$ 3.57$ 2.66
1 Total Debt Ratio 0.79 0.75 0.77 0.79 0.77
2 Interest Coverage Ratio 5.11 11.35 9.98 10.16 9.15
3 Capitalization Ratio 0.66 0.54 0.64 0.67 0.63
4 Debt/Equity Ratio 2.00 1.43 1.78 2.39 1.90
1 Inventory Turnover Ratio 7.37 6.48 7.28 7.30 7.11
2 Receivables turnover Ratio 5.60 4.80 5.91 6.37 5.67
3 Payables turnover Ratio 25.92 14.19 13.05 11.01 16.04
4 Fixed Assets Turnover Ratio 3.09 2.81 3.09 3.23 3.05
5 Total Assets Turnover Ratio 0.76 0.61 0.66 0.69 0.68
6 Asset to Equity Ratio 4.97 4.28 4.75 5.11 4.78
1 Price/Sales Ratio 2.29 2.70 2.29 2.70 2.49
2 Dividend Yield 2.52% 7.12% 7.43% 7.85% 6.23%
Operating Performance Ratios
Investment Valuation Ratios
SUMMARY OF RATIOS
Glaxo Smith Kline (GSK)
For
2010, 2011, 2012, 2013
Liquidity Measurement Ratios
Profitability Indicator Ratios
Financial Leverage Ratio
3 Price/Book Value Ratio 7.32 9.20 7.32 9.20 8.26
4 Price/Earnings Ratio 39.75 14.04 13.47 12.74 20.00
ABBOTReturn On Equity (ROE)
Net Income (NI)
Total Asset (TA)
Average Total Asset (Avg TA)
Shareholder Equity (ShEq)
Average Shareholder Equity (Avg ShEq)
Revenue (Rev)
Earnings before Taxes (EBT)
Earnings before Interest and Taxes (EBIT)
Formula:
DuPont is an “analysis” it’s a tool to compare a company to itself and to its competitors.
1. ROE
= (NI / Avg TA) x (Avg TA / Avg ShEq)
= ROA x Leverage
2. ROE
= (NI / Rev) x (Rev / Avg TA) x (Avg TA / Avg ShEq)
= Net Profit Margin x Asset Turnover x Leverage
3. ROE
= (NI / EBT) x (EBT / EBIT) x (EBIT / Rev) x (Rev / Avg TA) x (Avg TA / Avg ShEq)
= Tax Burden x Interest Burden x EBIT Margin x Asset Turnover x Leverage
Where:
ROE = Return on Equity
NI = Net Income
Avg TA = Average Total Assets
Avg ShEq = Average Shareholder Equity
Rev = Revenue
EBT = Earnings before Taxes
EBIT = Earnings before Interest and Taxes
ABBOT
Dupont Analysis
ABBOT
As of 31st December 2010, 2011, 2012
USD RS. in Rupees
Return On Equity (ROE)
Tax Burden
Interest Burden
EBIT Margin
Asset Turnover
Laverage
ROE
Abbot has strong ROE over the 3-years. The range is between 22% and 31%.
This range is a bit large, but is on the high side and the low is far above the 09% requirement.
Dec 31, 2010 Dec 31, 2011 Dec 31, 201221.69% 50.53% 11.42%
#REF! #REF! #REF!
14,891,799 15,437,585 16,243,325
4,020,700 6,597,875 8,367,595
10,799,814 11,108,572 11,471,591
2,515,112 4,549,361 5,946,788
18,916,191 21,750,147 23,149,964
1,931,724 2,236,888 2,312,096
#REF! #REF! #REF!
Dec 31, 2010 Dec 31, 2011 Dec 31, 2012
Dupont Analysis
ABBOT
As of 31st December 2010, 2011, 2012
USD RS. in Rupees
#REF! #REF! #REF!
#REF! #REF! #REF!
#REF! #REF! #REF!
#REF! #REF! #REF!
4.70470 3.29654 2.76662
1.59862 1.45029 1.40708
Description Dec 31, 2010 Dec 31, 2011 Dec 31, 2012
Cash Flow From Operating Activities
cash genrated from operations 3647883 1402378
financial charges pad -2369 -
staff retirement benefit paid -53016 -205481
taxes paid -1147359 -1061460
increase in long term loans to employees -12291 -8415
decrease in long term deposits 476 91
net cash generated from operating activities 2433324 127113
Cash Flow From Investing Activities
fixed capital expenditure -789884 -834597 -1497581
proceeds from sale of operating assets 34278 93840 152891
investimetns encashed - 175000 -
return on investiments PIBS 16275 7945 -
net cash used in investing activities -739331 -557812 -1344690
Cash Flow From Financing Activities
Dividend Paid -849019 -782165 -900008
Net(decrease)/Increase in cash and cash equivalents 844974 -1212864 -9888
cash and cash equivalents at beginning of the year 2693522 3538496 2325632
cash and cash equivalents at end of the year 3538496 2325632 2315744
Balance Sheet
Glaxo Smith Kline (GSK)
As of 31st December 2010, 2011, 2012
Rs. in (000)